CDMO News
Genetic Immunity Partners with VectorBuilder to Advance HIV Vaccine into Phase 3
Genetic Immunity, clinical-stage biotechnology company focusing on discovering and developing plasmid-based DNA (pDNA) therapeutic vaccines for cancer and infectious diseases, is taking its HIV vaccine into Phase 3 clinical trials following promising results from earlier studies. The company has partnered
4 December 2024
